To test this hypothesis, we evaluated the feasibility of combining radiation with BMS-690514, a potent, orally administrable inhibitor of VEGFR and EGFR tyrosine kinase activity that was shown to have in vitro anti-tumour activity against lung cancer cells in a panel of human NSCLC in vitro experiments (De La Motte Rouge et al, 2007). This evidence concerns the gene EGFR and lung cancer.